Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

pain.  The NKTR-181 Phase 2 study is a double-blind, placebo-controlled, randomized withdrawal study design evaluating the investigational drug candidate in patients with moderate to severe chronic pain from osteoarthritis of the knee.  Approximately 200 patients will be randomized to receive either NKTR-181 or placebo in the study.

NKTR-181 is an NCE (new chemical entity) which was created using Nektar's proprietary small molecule polymer conjugate technology and its potential differentiating properties are inherent to its molecular design.  In June of 2012, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to NKTR-181 for the treatment of moderate to chronic pain.

A Phase 1 clinical program for NKTR-181 has been completed in approximately 160 healthy volunteers.  These studies showed that NKTR-181 produced sustained and dose-dependent analgesic responses with twice-daily dosing over a period of 8 days.  These studies also measured the contraction of pupils over time following dosing with NKTR-181 and the data confirmed that NKTR-181 has a slow rate of entry into the CNS (central nervous system).  This slow rate of entry is designed to reduce the euphoria that can lead to abuse and addiction to current opioid analgesics.1 

Analyst Call to be Held 10:00 AM Pacific Time/1:00 PM Eastern Time on Wednesday, June 19, 2013The company will be hosting a call to discuss these data with analysts and investors at 10:00 AM Pacific time/1:00 PM Eastern time today.  Hosting the call will be Howard Robin, President and CEO of Nektar, and Robert Medve, MD, Chief Medical Officer.  Joining company management will be Sidney H. Schnoll, MD, PhD of PinneyAssociates, an internationally recognized expert in addiction and pain management. 

A live audio-only Webcast of the conference call c
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, announced today that ... Officer, will present live at VirtualInvestorConferences.com on March ... join us for this Company update," said Mr. ... commercial launch of the exVive3D Liver, Bioprinted Human ...
(Date:2/27/2015)... , Feb. 27, 2015  Two ... increasing in applications as their effectiveness is ... Kalorama Information.  Kalorama Information says that while ... the most powerful tool in proteomic biomarker ... MS) through its traditional techniques has struggled ...
(Date:2/26/2015)... 2015  Today the National Safety Council ... physical side effects of pain medications , ... Vicodin and Oxycontin, are safer options than over-the-counter pain ... painkillers than on heroin and cocaine combined," said ... "Yet, these medications are marketed as the Cadillac option ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2
... 24, 2011 The National Community Pharmacists ... and Consumer Choice Act of 2011 , which ... pharmacy of their choice, eliminate needless pharmaceutical spending ... pharmacy audits. (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ...
... Technologies, Inc . ( http://mindtechnologiesinc.com ) (Pink Sheets: ... The Company,s proprietary EEG/ BCI headset, which is currently ... world leader in EEG/ BCI technology, Mind Technologies assembled ... of developing a state-of-the-art headset that would revolutionize the ...
Cached Medicine Technology:Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 2Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 3Mind Technologies Inc. Developing Revolutionary EEG Brain Computer Interface 2
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
(Date:2/28/2015)... February 28, 2015 Pioneer Millworks reclaimed ... Japan Architecture & Construction Materials Show, an annual, premier ... than 1,000 suppliers and top manufacturers of the latest ... wood products sourced and manufactured by Pioneer Millworks ... popularity in Japan at restaurants, hotels, retailers, and corporate ...
(Date:2/28/2015)... February 28, 2015 India Network ... sponsored visitor health insurance programs for visitors coming to ... Indian elderly parents traveling to the United States are ... diabetes and blood pressure. These diseases are so common ... list them as medical conditions. There were 66.8 million ...
(Date:2/28/2015)... 28, 2015 How would you ... , There are all kinds of different leaders, ... awareness of the advantages and applications of different ... launching a new product this spring called The ... the connection between personality type, leadership, and success. ...
(Date:2/28/2015)... February 28, 2015 The noted Toronto ... Facial Surgery was recently featured in the January/February 2015 ... magazine, Dr. David Ellis was featured in an article ... various cosmetic enhancements that Kim Cattrall has possibly undergone ... “Her forehead is smooth without horizontal lines or frown ...
Breaking Medicine News(10 mins):Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Dr. David Ellis Featured In Elevate Magazine 2
... Amanda Gardner HealthDay Reporter , FRIDAY, Dec. 16 ... who receive targeted radiation to the breast after a lumpectomy ... only about a third of these women were considered "suitable" ... study published in the Dec. 16 online issue of the ...
... SAGE and the European Society of Cardiology (ESC) ... Journal: Acute Cardiovascular Care. The first issue will be ... represents over 70,000 cardiology professionals across Europe and the ... including publishing seven of the world,s leading cardiology journals. ...
... 17 (HealthDay News) -- The busy holiday season may disrupt ... it is especially important to remember to look after your ... people to consume sugary treats and drink alcoholic beverages more ... General Dentistry, said in an academy news release. "Additionally, ...
... Will a drug used to treat childhood acute lymphoblastic leukemia ... UB associate professor of pharmaceutical sciences, Javier G. ... research and clinical practice, has focused recent efforts on trying ... study in the Journal of Clinical Oncology looked for the ...
... Scientists may have a way to double the efficacy ... Sciences University scientists have devised a way to reduce lung ... caused by radiation therapy., "Radiation is a great therapy ... Dynan, biochemist and Associate Director of Research and Chief, Nanomedicine ...
... FRIDAY, Dec. 16 (HealthDay News) -- Chronic pain can ... the affected partner,s ability to cope with the pain, ... shown that validation of a spouse,s emotions (showing respect ... invalidation of emotions (showing hostility or no interest) increases ...
Cached Medicine News:Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 2Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 3Health News:Sage and European Society of Cardiology extend publishing partnership 2Health News:Dentist Gives Advice to Keep Holiday Smiles Bright 2Health News:Childhood cancer drugs cure now, may cause problems later, UB research shows 2Health News:Scientists may be able to double efficacy of radiation therapy 2Health News:Spouse's Reaction May Affect Pain Management 2
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
14 cm, very delicate, round cupped jaws, straight jaws, 3.0 mm...
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Spetzler titanium microsurgical instrument. Small spatula dissector, bayonet, angled up 30°....
Medicine Products: